Genetic Signature to Predict NAC Efficacy in Treating Idiopathic Pulmonary Fibrosis (IPF)
SUMMARY N-Acetylcysteine (NAC) is commonly used to break down mucous and lessen lung function decline but has traditionally shown low efficacy in treating patients with idiopathic pulmonary fibrosis (IPF). The only two FDA approved drugs to treat IPF have severe side effects, meaning there is an urgent need to find… Read More